$20.84
-0.50 (-2.34%)
HIMS News15 articles
Hims & Hers Stock Stabilizes as Novo Deal Shifts Focus to Profitability
Hims & Hers Health shares traded near $23.82 Friday, stabilizing after a week of volatility driven by its new branded obesity drug agreement with Novo Nordisk. The shift from compounded medications raises margin concerns despite reducing regulatory risk.
Hims & Hers Stock Extends Rally on Novo Nordisk Patent Settlement
Shares of Hims & Hers Health continued their ascent following a resolution to a patent conflict with Novo Nordisk, which will reintroduce branded GLP-1 medications to its service. Analysts have upgraded the stock but caution about potential margin pressures.
Hims & Hers Soars on Novo Nordisk Partnership, Analyst Targets Rise
Shares of Hims & Hers Health skyrocketed approximately 49% over two sessions following a new distribution agreement with Novo Nordisk. The deal resolves a legal dispute and will bring branded GLP-1 drugs to the telehealth platform, leading several analysts to raise their price targets.
Markets Brace for Inflation Data as Oil Surge Dents Rate Cut Hopes
U.S. equity futures declined sharply Monday amid surging oil prices and weak jobs data, pushing back expectations for Federal Reserve rate cuts. Investors await critical inflation reports due this week.
Hims & Hers Shares Jump on Novo Nordisk Partnership Revival
Hims & Hers Health shares surged in premarket trading Monday following reports that Novo Nordisk will resume selling its weight-loss drugs through the telehealth platform. The move marks a reversal from a patent dispute last month.
Hims & Hers Faces SEC Probe, Novo Nordisk Lawsuit as Analysts Cut Targets
Hims & Hers Health shares held steady premarket following disclosures of an SEC probe and a patent lawsuit from Novo Nordisk. Analysts at BTIG and Citi downgraded the stock, citing regulatory risks.
Hims & Hers Shares Stabilize After Novo Nordisk Patent Lawsuit Rattles Weight-Loss Strategy
Hims & Hers stock edged up 0.1% premarket following steep declines after Novo Nordisk filed a patent lawsuit over compounded semaglutide. Investors await court developments, FDA signals, and the company's Feb. 23 earnings.
Hims & Hers Stock Extends Slide Amid Weight-Loss Pill Halt, Regulatory Pressure
Hims & Hers Health shares fell another 4.2% premarket Tuesday, compounding a 16% drop Monday, after discontinuing its compounded semaglutide pill. The company faces a patent lawsuit from Novo Nordisk and potential FDA action.
Hims & Hers Shares Plunge 16% After Halting $49 Weight-Loss Pill Amid Novo Nordisk Lawsuit
Hims & Hers Health stock tumbled in after-hours trading following the withdrawal of its compounded semaglutide product and a patent infringement lawsuit from Novo Nordisk. Leerink Partners reduced its price target on the company.
Dow Futures Edge Higher Amid Mixed Premarket Action, Focus on Jobs and CPI Data
U.S. stock futures were mixed early Monday, with Dow futures gaining while S&P 500 and Nasdaq 100 futures dipped. Investors await key January employment and inflation reports later this week.
Novo Nordisk Shares Surge as Hims Abandons Low-Cost Semaglutide Pill
Novo Nordisk stock climbed over 8% after Hims & Hers canceled plans for a $49 compounded weight-loss pill. The move follows FDA warnings against unapproved GLP-1 drug marketing.
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
Hims Halts Compounded GLP-1 Pill as FDA Cracks Down, Molina Plunges on Profit Warning
Hims & Hers discontinues its $49 compounded semaglutide offering following FDA enforcement signals, sending shares down 16%. Molina Healthcare forecasts 2026 profit far below expectations, triggering a 28% stock drop.
Hims & Hers Shares Extend Decline Amid Novo Nordisk Patent Lawsuit Over Compounded Weight-Loss Drugs
Hims & Hers Health stock fell another 5.6% as Novo Nordisk filed a patent lawsuit seeking to block compounded versions of Wegovy, tightening regulatory pressure on the online health provider's GLP-1 offerings.
Novo Nordisk Shares Rebound as Hims Halts Wegovy Copycat After FDA Pressure
Novo Nordisk's Class B shares surged 5.3% after Hims & Hers discontinued its compounded Wegovy pill following U.S. regulatory warnings. The stock had dropped nearly 8% when the copycat launched.